Oral dyskinesia: A clinical overview

International Journal of Prosthodontics

Volumn 18, Issue 1, 2005, Pages 10-19

  Blanchet, Pierre J ^a,b   Rompré, Pierre H ^a   Lavigne, Gilles J ^a   Lamarche, Claude ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BENSERAZIDE PLUS LEVODOPA; BENZATROPINE; BENZATROPINE MESILATE; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; CHLORPROMAZINE; CIMETIDINE; CLOZAPINE; DIPHENHYDRAMINE; DOXEPIN; DURALITH; FLUOXETINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HALOPERIDOL; IMIPRAMINE; LEVODOPA; LEVOMEPROMAZINE; LITHIUM; LITHIUM CARBONATE; METOCLOPRAMIDE; OLANZAPINE; PAROXETINE; PERPHENAZINE; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PRIMIDONE; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; PROCYCLIDINE; PROMETHAZINE; QUETIAPINE; RANITIDINE; RISPERIDONE; SERTRALINE; THIOPROPERAZINE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; UNINDEXED DRUG;

CLINICAL FEATURE; DENTAL CARE; DENTISTRY; DENTURE; DIFFERENTIAL DIAGNOSIS; DYSKINESIA; DYSTONIA; HEALTH SURVEY; HUMAN; INVOLUNTARY MOVEMENT; MEDICAL LITERATURE; MEDLINE; NEUROPSYCHIATRY; REVIEW; TOOTH PROSTHESIS;

BRUXISM; DENTAL CARE; DENTURES; DYSKINESIA, DRUG-INDUCED; DYSKINESIAS; HUMANS; MOUTH DISEASES; MOUTH, EDENTULOUS; STEREOTYPED BEHAVIOR; TIC DISORDERS;

EID: 13444267441     PISSN: 08932174     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Villeneuve A. The rabbit syndrome: A peculiar extrapyramidal reaction. Can Psychiatr Assoc J 1972;17(suppl 2):SS69-SS72.
2. Yassa R, Lal S. Prevalence of the rabbit syndrome. Am J Psychiatry 1986;143:656-657.
3. Schwartz M, Hocherman S. Antipsychotic-induced rabbit syndrome: Epidemiology, management and pathophysiology. CNS Drugs 2004;18:213-220.
4. Bassett A, Remick RA, Blasberg B. Tardive dyskinesia: An unrecognized cause of orofacial pain. Oral Surg Oral Med Oral Pathol 1986;61:570-572.
5. Blanchet PJ, Abdillahi O, Beauvais C, Rompré PH, Lavigne GJ. Prevalence of spontaneous oral dyskinesia in the elderly: A reappraisal. Mov Disord 2004;19:892-896.
6. Osborne TE, Grace EG, Schwartz MK. Severe degenerative changes of the temporomandibular joint secondary to the effects of tardive dyskinesia: A literature review and case report. J Craniomandib Pract 1989;7:58-62.
7. Faurbye A, Rasch PJ, Petersen PB, Brandborg G, Pakkenberg H. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand 1964;40:10-27.
8. Casey DE. Neuroleptic-induced extrapyramidal syndromes and tardive dyskinesia. In: Hirsch S, Weinberger DR (eds). Schizophrenia. Oxford, UK: Blackwell, 1995:546-565.
9. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: Prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8(4 suppl):52S-56S.
10. Woerner MG, Alvir JMJ, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors. Am J Psychiatry 1998;155:1521-1528.
11. Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry 2000;61(suppl 4):27-32.
12. Kapitany T, Meszaros K, Lenzinger E, et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998;32:101-106.
13. Lam LC, Garcia-Barcelo MM, Ungvari GS, et al. Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry 2001;34:238-241.
14. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105-119.
15. Casey DE. Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia? Int Clin Psychopharmacol 1997;12(suppl 1):S19-S27.
16. Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001;11(suppl 4):S397-S403.
17. Halliday J, Farrington S, MacDonald S, MacEwan T, Sharkey V, McCreadie R. Nithsdale Schizophrenia Surveys 23: Movement disorders. Br J Psychiatry 2002;181:422-427.
18. Barnes TRE, Kidger T, Gore SM. Tardive dyskinesia: A 3-year follow-up study. Psychol Med 1983;13:71-81.
19. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986;22:254-258.
20. Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 2001;56:805-807.
21. Blanchet PJ. Antipsychotic drug-induced movement disorders. Can J Neurol Sci 2003;30(suppl 1):S101-S107.
22. Myers DE, Schooler NR, Zullo TG, Levin H. A retrospective study of the effects of edentulism on the severity rating of tardive dyskinesia. J Prosthet Dent 1993;69:578-581.
23. Sandyk R, Kay SR. Edentulousness and neuroleptic-induced neck and trunk dyskinesia. Funct Neurol 1990;5:361-363.
24. Sutcher H, Soderstrom J, Perry R, Das A. Tardive dyskinesia: Dental prosthetic therapy. Panminerva Med 1998;40:154-156.
25. Fann WE, Sullivan JL, Richman BW. Dyskinesias associated with tricyclic antidepressants. Br J Psychiatry 1976;128:490-493.
26. Vandel P, Bonin B, Leveque E, Sechter D, Bizouard P. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol 1997;7:207-212.
27. Ellison JM, Stanziani P. SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry 1993;54:432-434.
28. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996;57:449-454.
29. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998;32:692-698.
30. Bostwick JM, Jaffee MS. Buspirone as an antidote to SSRI-induced bruxism in 4 cases. J Clin Psychiatry 1999;60:857-860.
31. Winocur E, Gavish A, Voikovitch M, Emodi-Perlman A, Eli I. Drugs and bruxism: A critical review. J Orofac Pain 2003;17:99-111.
32. Daras M, Koppel BS, Atos-Radzion E. Cocaine-induced choreoathetoid movements ("crack dancing"). Neurology 1994;44:751-752.
33. Ashcroft GW, Eccleston D, Waddell JL. Recognition of amphetamine addicts [letter]. Br Med J 1965;1:57.
34. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988;1:273-277.
35. Milosevic A, Agrawal N, Redfearn PJ, Mair LH. The occurrence of toothwear in users of ecstasy (3,4 methylenedioxymethamphetamine). Community Dent Oral Epidemiol 1999;27:283-287.
36. Nixon PJ, Youngson CC, Beese A. Tooth surface loss: Does recreational drug use contribute? Clin Oral Invest 2002;6:128-130.
37. Koller WC. Edentulous orodyskinesia. Ann Neurol 1983;13:97-99.
38. Jeste DV, Wyatt RJ. Changing epidemiology of tardive dyskinesia: An overview. Am J Psychiatry 1981;138:297-309.
39. Villeneuve A, Turcotte J, Bouchard M, Côté JM, Jus A. Release phenomena and iterative activities in psychiatric geriatric patients. Can Med Assoc J 1974;110:147-153.
40. Torrey EF. Studies of individuals with schizophrenia never treated with antipsychotic medications: A review. Schizophr Res 2002;58:101-115.
41. McCreadie RG, Padmavati R, Thara R, Srinivasan TN. Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. Br J Psychiatry 2002;181:135-137.
42. Owens DG, Johnstone EC, Frith CD. Spontaneous involuntary disorders of movement: Their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry 1982;39:452-461.
43. Barnes TRE, Rossor M, Trauer T. A comparison of purposeless movements in psychiatric patients treated with antipsychotic drugs, and normal individuals. J Neurol Neurosurg Psychiatry 1983;46:540-546.
44. Delwaide PJ, Desseilles M. Spontaneous buccolinguofacial dyskinesia in the elderly. Acta Neurol Scand 1977;56:256-262.
45. Sulkava R. Alzheimer's disease and senile dementia of Alzheimer type: A comparative study. Acta Neurol Scand 1982;65:636-650.
46. Molsa PK, Marttila RJ, Rinne UK. Extrapyramidal signs in Alzheimer's disease. Neurology 1984;34:1114-1116.
47. Degkwitz R, Wenzel W. Persistent extrapyramidal side effects after long-term application of neuroleptics. In: Brill H, Cole JO, Deniker P, Hippius H, Bradley PB (eds). Neuro-Psycho-Pharmacology. International Congress Series No. 129. Amsterdam: Excerpta Medica Foundation, 1967:608-615.
48. Crane GE. Persistent dyskinesia. Br J Psychiatry 1973;122:395-405.
49. Bourgeois M, Boueilh P, Tignol J. Spontaneous dyskinesia in the elderly and tardive dyskinesia of neuroleptics. A survey among 270 patients [author's transl; in French]. Encephale 1980;6:37-39.
50. Blowers AJ, Borison AL, Blowers CM, Bicknell DJ. Abnormal involuntary movements in the elderly. Br J Psychiatry 1981;139:363-364.
51. Kane JM, Weinhold P, Kinon B, Wegner J, Leader M. Prevalence of abnormal involuntary movements ("spontaneous dyskinesias") in the normal elderly. Psychopharmacology 1982;77:105-108.
52. D'Alessandro R, Benassi G, Cristina E, Gallassi R, Manzaroli D. The prevalence of lingual-facial-buccal dyskinesias in the elderly. Neurology 1986;36:1350-1351.
53. Tublin LM. A treatment for tardive dyskinesia in a complete denture patient. A case report. N Y State Dent J 1989;55:30.
54. Frucht S, Fahn S, Ford B, Gelb M. A geste antagoniste device to treat jaw-closing dystonia. Mov Disord 1999;14:883-886.
55. Kato T, Blanchet PJ, Montplaisir JY, Lavigne GJ. Sleep bruxism and other disorders with orofacial activity during sleep. In: Chokroverty S, Hening WA, Walters AS (eds). Sleep and Movement Disorders. Philadelphia: Butterworth Heinemann, 2003:273-285.
56. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982;32:1335-1346.
57. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 1998;121:2053-2066.
58. Altrocchi PH, Forno LS. Spontaneous oral-facial dyskinesia: Neuropathology of a case. Neurology 1983;33:802-805.
59. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995;18:197-214.
60. Sankhla C, Lai EC, Jankovic J. Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry 1998;65:722-728.
61. Schrag A, Bhatia KP, Quinn NP, Marsden CD. Atypical and typical cranial dystonia following dental procedures. Mov Disord 1999;14:492-496.
62. Tan E-K, Chan L-L, Chang H-M. Severe bruxism following basal ganglia infarcts: Insights into pathophysiology. J Neurol Sci 2004;217:229-232.
63. Tison F, Louvet-Giendaj C, Henry P, Lagueny A, Gaujard E. Permanent bruxism as a manifestation of the oculo-facial syndrome related to systemic Whipple's disease. Mov Disord 1992;7:82-85.
64. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-362.
65. Stip E, Faughnan M, Desjardins I, Labrecque R. Botulinum toxin in a case of severe tardive dyskinesia mixed with dystonia. Br J Psychiatry 1992;161:867-868.
66. Tarsy D, Kaufman D, Sethi KD, Rivner MH, Molho E, Factor S. An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 1997;20:90-93.
67. Kanovsky P, Streitova H, Bares M, Hortova H. Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: Evidence of a long-lasting effect. Mov Disord 1999;14:886-888.
68. Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc 2000;131:211-216.
69. Weetman J, Anderson IM, Gregory RP, Gil SS. Bilateral posteroventral pallidotomy for severe antipsychotic induced tardive dyskinesia and dystonia. J Neurol Neurosurg Psychiatry 1997;63:554-556.
70. Wang Y, Turnbull I, Calne S, Stoessl AJ, Calne DB. Pallidotomy for tardive dyskinesia. Lancet 1997;349:777-778.
71. Trottenberg T, Paul G, Meissner W, Maier-Hauff K, Taschner C, Kupsch A. Pallidal and thalamic neurostimulation in severe tardive dystonia. J Neurol Neurosurg Psychiatry 2001;70:557-559.
72. Sutcher HD, Underwood RB, Beatty RA, Sugar O. Orofacial dyskinesia - A dental dimension. J Am Med Assoc 1971;216:1459-1463.
73. Lauciello F, Appelbaum M. Prosthodontic implications of tardive dyskinesia. N Y State Dent J 1977;43:214-217.
74. Watanabe I, Yamane G, Yamane H, Shimono M. Oral dyskinesia of the aged: II. Electromyographic appearances and dental treatment. Gerodontics 1988;4:310-314.
75. Chiodo GT, Rosenstein DI. Tardive dyskinesia. Gen Dent 1990;38:289-291.
76. Kai S, Kai H, Tashiro H. Tardive dyskinesia affected by occlusal treatment - A case report. J Craniomandib Pract 1994;12:199-203.
77. Payne AGT, Carr L. Can edentulous patients with orofacial dyskinesia be treated successfully with implants? A case report. J Dent Assoc S Afr 1996;51:67-70.
78. Kelleher MGD, Scott BJJ, Djemal S. Case report: Complications of rehabilitation using osseointegrated implants - Tardive dyskinesia. Eur J Prosthodont Restorative Dent 1998;6:133-136.